Although KRAS is able to directly activate PI3K signaling by binding to p110-PI3K subunit, there is increasing evidence that PI3K activation following MEK inhibition is correlated to RTK activity, paving the way to the use of RTK inhibitors in KRAS mutated CRC [20]. Here, KRAS is linked to colorectal carcinoma.